| # | Drug | Count |
|---|---|---|
| 0 | DUPILUMAB | 1538 |
| 1 | DICLOFENAC SODIUM | 771 |
| 2 | VEDOLIZUMAB | 579 |
| 3 | ERGOCALCIFEROL | 499 |
| 4 | PRABOTULINUM TOXIN TYPE A | 469 |
| 5 | PREDNISONE | 393 |
| 6 | EPTINEZUMAB-JJMR | 383 |
| 7 | IBUPROFEN | 378 |
| 8 | ACETAMINOPHEN | 335 |
| 9 | OFATUMUMAB | 321 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | LETIBOTULINUMTOXINA-WLBG | 81 | 0.2765 |
| 1 | FLOTUFOLASTAT F-18 | 8 | 0.1633 |
| 2 | PRABOTULINUM TOXIN TYPE A | 469 | 0.1241 |
| 3 | ACECLIDINE | 76 | 0.1034 |
| 4 | LEVOKETOCONAZOLE | 54 | 0.0714 |
| 5 | ACETAMINOPHEN AND IBUPROFEN | 15 | 0.0679 |
| 6 | POTASSIUM NITRATE, SODIUM FLUORIDE | 42 | 0.0656 |
| 7 | IBUPROFEN, ACETAMINOPHEN | 147 | 0.0527 |
| 8 | ADALIMUMAB-RYVK | 45 | 0.0413 |
| 9 | ACETAMINOPHEN, IBUPROFEN | 15 | 0.0405 |
| # | Drug class | Count |
|---|---|---|
| 0 | Interleukin-4 Receptor alpha Antagonist [EPC] | 1538 |
| 1 | Nonsteroidal Anti-inflammatory Drug [EPC] | 1261 |
| 2 | Corticosteroid [EPC] | 841 |
| 3 | Acetylcholine Release Inhibitor [EPC] | 626 |
| 4 | Neuromuscular Blocker [EPC] | 624 |
| 5 | Integrin Receptor Antagonist [EPC] | 579 |
| 6 | Provitamin D2 Compound [EPC] | 499 |
| 7 | CD20-directed Cytolytic Antibody [EPC] | 430 |
| 8 | Benzodiazepine [EPC] | 410 |
| 9 | Platelet Aggregation Inhibitor [EPC] | 389 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Interleukin-5 Antagonist [EPC] | 132 | 0.1919 |
| 1 | Cortisol Synthesis Inhibitor [EPC] | 54 | 0.0714 |
| 2 | Calcitonin Gene-related Peptide Antagonist [EPC] | 383 | 0.0393 |
| 3 | Dopamine and Norepinephrine Reuptake Inhibitor [EPC] | 72 | 0.0187 |
| 4 | Provitamin D2 Compound [EPC] | 499 | 0.0168 |
| 5 | Guanylate Cyclase-C Agonist [EPC] | 31 | 0.0149 |
| 6 | Bispecific HER2-directed Antibody [EPC] | 1 | 0.0122 |
| 7 | Plasma Kallikrein Inhibitor [EPC] | 29 | 0.0121 |
| 8 | APOC-III-directed RNA Interaction [EPC] | 1 | 0.0096 |
| 9 | Neonatal Fc Receptor Blocker [EPC] | 41 | 0.0093 |